Concepedia

J. M. Cleary

JM

8

Publications

169

Citations

8

H-Index

2002

Active since

Affiliations

University of Wisconsin System(Current)

J. M. Cleary is an author at University of Wisconsin System specializing in pharmacology, oncology, and cancer therapeutics.

Top concepts

MedicineOncologyPharmacologyCancer TherapyCancer ResearchPharmacotherapyMolecular OncologyTumor BiologyRadiation OncologyPre-clinical Pharmacology

Publications per year

2002–2011

8

Publications

8

Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.

Geoffrey I. Shapiro, P. LoRusso, E. L. Kwak et al. · Journal of Clinical Oncology · 2011 · 44 citations

Pathology, Pi3k/akt Signaling Pathways, Pi3k Inhibitor +17

Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.

Alan L. Ho, J. C. Bendell, J. M. Cleary et al. · Journal of Clinical Oncology · 2011 · 33 citations

Xenograft Models, Pathology, Pharmacotherapy +19

Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats.

Joseph Merchant, Kendra D. Tutsch, Amy Dresen et al. · PubMed · 2002 · 20 citations

A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors.

J. M. Cleary, Elisabeth I. Heath, E. L. Kwak et al. · Journal of Clinical Oncology · 2010 · 20 citations

Solid Tumors, Cancer Management, Next-generation Hsp90 Inhibitor +20

A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report.

D. C. Cho, Elisabeth I. Heath, J. M. Cleary et al. · Journal of Clinical Oncology · 2011 · 18 citations

Solid Tumors, Hsp90 Inhibitor Ganetespib, Pharmacotherapy +17

Rows per page

1–5 of 8